SCHEMBL3405341

SCHEMBL3405341

CCN(CC)CCNC(=O)c1sc(-c2ccc(Cl)cc2Cl)nc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
MAPT P10636 2/20 0.51
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 3/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 2/20 0.43
SHMT1 P34896 1/20 0.42
SHMT2 P34897 1/20 0.42
PDE2A O00408 1/20 0.42
KDR P35968 1/20 0.42
PRKAA2 P54646 1/20 0.42
PRKAA1 Q13131 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3398938 0.92 GAA (0.46) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL14545475 0.88 KDM4E (0.46) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL3399671 0.87 MAPT (0.47) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL3401069 0.86 MAPK1 (0.48) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL3403957 0.83 PANK3 (0.46) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL13071981 0.82 MAPT (0.52) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL3399977 0.82 TSHR (0.53) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL3437699 0.81 GAA (0.68) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL3401355 0.80 DPP4 (0.54) KDM4EMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL3400943 0.79 DPP4 (0.56) KDM4EMAPTGAAALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 KDM4E 3449/4885MAPT 342/4885GAA 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.